Previous studies demonstrated that the frequency of donorversus-host-reactive cytotoxic T-cell precursors (CTL-p) before allogeneic bone marrow transplantation (BMT) from matched unrelated donors correlates with the incidence of graft-versus-host disease (GvH-D). We investigated whether clinical manifestations of GvH-D after HLA-identical sibling BMT are accompanied by an increased frequency of minor histocompatibility antigen (HA)-specific CTL-p. We further asked whether changes of third-party-reactive CTL-p as a measure of overall immunocompetence are related t o infectious complications frequently seen immediately after BMT. Eighteen patients (16 with an HLA-identical bone marrow graft, two with either one HLA-A or one HLA-DR mismatch) were studied. Limiting dilution analysis (LDA) was used t o assess donor CTL-p frequencies against recipient pre-BMT, donor, and third-party targets in a follow-up study. Eight cases receiving HLA-identical marrow grafts never developed signs of GvH-D. Undetectable or very low frequencies (1 1131,458) of minor HA-specific CTL-p were demonstrated pre-BMT. Two recipients, one of an HLA-A-and one of an HLA-DR-mismatched graft, exhibited low frequencies of recipient-specific CTLp (1 166,920 and 1185,577, respectively) before transplantation, which further decreased despite mild GvH-D grade l, or decreased within 3 months after
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LLOGENEIC bone marrow transplantation (BMT) is
A successfully used for the treatment of hematological malignancies, severe aplastic anemia, and congenital immunodeficiency ~tates."~ Despite the use of matched donors and prophylactic immunosuppression, graft-versus-host disease (GvH-D) still represents a frequent compli~ation.~ T lymphocytes are crucially involved in the pathogenesis of the disease.637 In the case of HLA-identical BMT, these cells were shown to recognize minor histocompatibility antigen (HA) in a major histocompatibility complex (MHC)- (LDA) of allo-MHC-reactive cytotoxic T-cell precursors (CTL-p) in HLA phenotypically matched donor lymphocytes indicated that their pre-BMT frequencies were predictive of the incidence of GvH-D subsequent to matched unrelated BMT." In this study, we investigated post-BMT minor HA-specific C T L p and their relationship to development of GvH-D. BMT leads to a profound and prolonged immune deficiency state, which renders these patients susceptible to a variety of infectious Particularly, cytomegalovirus (CMV) infection occurs frequently after allogeneic BMT. 13 We used LDA to quantify the reactivity against HLA nonidentical third-party cells as a measure of the patients' overall cellular immune reactivity and searched for a relationship with infectious complications subsequent to BMT.
MATERIAL AND METHODS

Patients
Eighteen allogeneic bone marrow graft recipients were entered into the study. Underlying diseases were chronic myelogenous leukemia (CML, n = 7), acute myeloid leukemia (AML, n = 6), acute lymphoblastic leukemia (ALL, n = 2), Burkitt lymphoma (n = 2), and Hodgkin's disease (n = 1). Sixteen patients were grafted from their HLA-identical and mixed lymphocyte culture nonreactive sibling donors. Two patients with CML received a bone marrow graft from their one-antigen mismatched sibling donors. Details of the clinical characteristics, HLA typing of patients, donors and third-party test cells are shown in Table 1 .
Pretransplant conditioning for hematopoietic malignancies consisted of high-dose cyclophosphamide 60 mglkg on days -6 and -5, followed by fractionated total body irradiation of 12 Gy on days -3 to -1. Patients were prophylactically immunosuppressed with cyclosporine A (CyA) and methotrexate or CyA alone (Table 1) following previously published standard regimen^.'^.'' Patients 8, 14 , and 17 underwent fractionated total body irradiation (12 Gy) and subsequently received cyclophosphamide 50 mg/kg for 4 consecutive days as previously described.I6 Successful engraftment leading to self-sustaining hematopoiesis, and complete hemolymphopoietic chimerism was achieved in all 18 patients. This was proved either by determination of erythrocyte antigens of donor type after BMT, by the presence of different sex chromosomes in case of a sex difference between donor and recipient, or by isoenzyme analysis." GvH-D was diagnosed on clinical and histological grounds and graded according to established criteria.' Treatment was started in patients with GvH-D grade I1 or more according to previously described protocols." High-dose methylprednisolone was started at a dosage of 1,OOO mg/d, reduced to 500 mg the second day, and continued at 0.5 mglkg until resolution of symptoms. Two patients (no. 14 and 17) were additionally treated with 18 mg/d of the CD3-reactive monoclonal antibody BMA 031 during an early acute GvH-D, according to a recently published work.I9
Laboratov Investigations
Isolation, preparatwn, and storage of responder and stimulator cells. Peripheral blood mononuclear cells (PBMC) were collected from the patients before, once or twice after BMT, or at the time of GvH-D, as well as from the donors and normal third-party persons.
Cells were isolated by centrifugation on Lymphoprep (Nygaard, Oslo, Norway) from heparinized (50 U/mL) venous blood as described elsewhere.w PBMC were cryopreserved at a density of 5 to 30 X 106/mL in 10% dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany), 50% heat-inactivated male pool serum (PS), and 40% tissue culture medium RPMI 1640 (Biochrom, Berlin, Germany) in liquid nitrogen?' At the time of testing, cells were thawed quickly in 1 mL PS and washed three times in complete tissue culture medium.
LDA and CTL-pfrequencies. LDA were performed as recently described by Kaminski et direction before and at various times after BMT. Graded numbers (starting with 50,000 down to 100 cells/culture) were cocultured with 50,000 irradiated (30 Gy) stimulator cells per well. From every dilution step, 24 replicates were assessed in round-bottomed microtiter plates (Flow Laboratories, Meckenheim, Germany). Culture medium RPMI 1640 was supplemented with 10% PS, antibiotics, antimycotics, and 2 mmol/L L-glutamine. On days 3 and 6, a final concentration of 5 U/mL of recombinant human interleukin-2 (rIL-2) was added to the cultures. rIL-2 was kindly provided from Dr E. Liehl, Sandoz Forschungsinstitut, Vienna, Austria. Irradiated recipient pre-BMT cells, and in parallel unrelated third-party cells, were used as stimulators. After 10 days of culture at 37°C in a humidified 5% CO,, 95% air atmosphere, each microculture was individually tested for cytolytic activity against phytohemagglutinin (PHA)-driven "Cr-labeled recipient pre-BMT or third-party target cells. Split-well cultures were also tested against donor targets as controls. Blast transformation was achieved by culturing cells with 2 pg/mL PHA (Difco, Detroit, MI) in tissue culture medium for 3 days. After cell adjustment to 2 x 10S/mL, rIL-2 was added at a h a 1 concentration of 25 U/mL for a further 2 days. To each well, 100 pL medium containing 10,000 target blasts was added and the microcultures incubated for a further 4 hours at 37°C. Subsequently, 100 pL of supernatant was harvested and assessed for gamma radiation in a well-type gamma counter (LKB, Wallac, 1272, Clinigamma, Finland) linked to a personal computer (IBM, 34XT; Armonk, New York, NY). Spontaneous "Cr release was determined from wells containing only irradiated stimulator cells. A suspension of 100 pL target cells was used as maximum release. The percentage of specific lysis was calculated as % specific lysis = [(cpm,, -c~q~J / ( c p n~,~ -cpm spn,)] x 100.
Frequencies of CTLp were calculated according to Taswell using the chi-square minimization procedure.u For calculation, all cultures with cytolytic values greater than the mean spontaneous release plus 3 SD were included in the analysis. The probability of single-hit conditions and the definition of the 95% confidence interval were determined using a computer program based on statistical methods also described by Taswell.' Details were previously reported by Irschick et a1?4
Statistical unabsis.
For
RESULTS
CTL-p frequencies from the donor and the recipient post-BMT were determined against recipient pre-BMT cells, donor cells, and third-party cells. Sixteen recipientdonor combinations were HLA-identical; two further cases had one HLA-A and one HLA-DR mismatch, respectively. Nine of the 18 patients subsequently developed acute and/or chronic GvH-D, which in five cases required additional immunosuppressive therapy (Tables 1 and 2 ).
Before BMT, both patients receiving a mismatched graft (no. 17 and 18), but only one of 16 cases with a matched graft (no. 5), exhibited detectable alloantigen-specific C T L p frequencies. Patients with mismatched donors also displayed anti-host-reactive C T L p frequencies (1/66,920 and 1/85,577 respectively) higher than the single case with a measurable C T L p frequency before matched sibling grafting (1/131,458, Table 2 ). Of the two mismatched BMT recipients, one patient (no. 17) subsequently developed For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
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mild GvH-D with a significant decrease of host-reactive CTLp frequencies after BMT. In two further cases (no. 5 and 18) with detectable host-reactive CTLp before BMT, only a minimal decrease was seen after BMT ( Table 2 ). An example of an LDA plot of host-reactive CTL-p frequencies of patient 5 grafted with an HLA-identical sibling bone marrow is shown in Fig 1. The other 15 bone marrow recipients displayed host-reactive CTLp frequencies of less than 1/300,000 before BMT ( Table 2) of four patients exhibiting GvH-D grades I1 to I11 (median CTLp frequencies, 1/111.970), a statistically significant difference was detectable (P < .05, Mann-Whitney U test).
In all cases, split-well cultures were also tested in parallel against donor targets. No detectable CTLp frequencies against donor targets were seen at any tested times.
As expected, third-party-reactive CTL-p frequencies were detectable in all patients before grafting ( Table 2 and Fig 3) . A strong drop to an average of one third of the normalized pretransplant values (median, 33%) was observed. The difference between normalized pre-and post-BMT values reached statistical significance (P < .02, Wilcoxon matched-pairs signed-rank test). Also, the difference between absolute CTLp frequencies was statistically significant (median, 1/4,417 pre-BMT; 1/14,289 post-BMT; P < .01). In five cases, frequencies were too low to be detectable after BMT. CTL-p frequencies against thirdparty cells were compared between patients with and without transplant-related complications such as GvH-D and severe infections. The patient group with GvH-D andlor life-threatening infections also showed a strong diminution of third-party-reactive CTL-p frequencies to 35% of pre-BMT values. This reduction was also observed in patients without transplant-related complications, reaching a median of 26% of the pretransplant values, but the difference between patients with and without complications was not statistically significant (P < .4, Wilcoxon matchedpairs signed-rank test).
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From evaluate the pool size of host-specific CTLp after MHCmatched and -mismatched human BMT. As a potentially meaningful parameter to determine alloreactivity, we investigated in detail: (1) the presence of donor-reactive C T L p frequencies; (2) the predictive value of recipient-specific C T L p frequencies for GvH-D before HLA-matched or -mismatched BMT; (3) the frequency of host-specific CTLp after BMT and its relationship to clinical manifestation of GvH-D; and (4) the impact of BMT on frequencies of third-party-reactive C T L p and the relationship to infections.
Our results obtained from a pilot group of patients indicate that expansion of minor HA-specific CTL-p subsequent to BMT relates to clinical manifestation of severe GvH-D. They also suggest that a severe depletion of the alloreactive CTL-p pool occurs subsequent to BMT. In agreement with Kaminski et a1," we observed that, within the limits of detection in recipients of related matched donor bone marrow, determination of minor HA-specific CTLp frequencies does not enable prediction of GvH-D. Also, in keeping with the findings of Kaminski et al, we observed higher frequencies of host-reactive CTLp in donor cells mismatched for HLA before transplantation. Finally, no donor-reactive CTLp were found at any time tested.
CTLs are key effector cells during allograft rejection and GvH-D. Enlargement of the donor-specific CTLp pool was observed during rejection in different animal ~y s t e m s~j '~~ and in man, including kidney and highly vascularized corneal allografts.24345 In contrast, tolerance in these two clinical situations was invariably associated with a reduction of donor-specific CTLp frequen~ies.'~,~~ In human BMT recipients, we observed an increase in circulating hostspecific CTLp during severe multiorgan GvH-D, but no enlargement of this pool in patients without or with mild GvH-D. However, while third-party-specific CTL-p reduction in solid organ transplantation was not observed, in BMT a profound decrease in third-party-reactive CTL-p was detected. The increase in minor HA-specific CTL-p frequencies during GvH-D is in keeping with published data from Hamilton et al in a murine system? and after human HLA-identical BMT. Anti-host-directed CTL effectors were isolated after HLA-identical BMT during GvH-D.8,',47 As CTL effectors were generated not only during GvH-D, and since even in mismatched transplant recipients the presence of a large pool of host-reactive CTLp is not always associated with GvH-D, we conclude that other factors are also crucial in determining the evolution of GvH-D. Similar conclusions on the basis of a different technology were recently reached by van Els et aL4' Cytokinemediated control of target susceptibility and T-helper cell activity might represent other variables not determined by genetic polymorphism. The participation of helper T lymphocytes in response to minor HA was recently de~cribed.~'
In conclusion, our data suggest that in human allogeneic BMT recipients there exists a pool of non-HLA-specific CTL-p, which probably represents cells specific for minor HA. This can be specifically activated despite a general depletion of the alloreactive CTL pool and, when enlarged, is associated with GvH-D. In addition to this pool of minor HA-specific CTLs, patients transplanted across HLA mismatches have an additional pool of allo-MHC-specific CTLs.
